Imaging markers for Alzheimer disease: which vs how - Test2 - elhamkhani - TriplyDB

Imaging markers for Alzheimer disease: which vs how

Imaging markers for Alzheimer disease: which vs how

http://www.wikidata.org/entity/Q27001254

about

18 F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study Structural imaging measures of brain aging.Advances in MRI biomarkers for the diagnosis of Alzheimer's disease.Current status and future role of brain PET/MRI in clinical and research settings.Structural Neuroimaging of the Medial Temporal Lobe in Alzheimer's Disease Clinical Trials.PET Neurochemical Imaging Modes.White matter damage disorganizes brain functional networks in amnestic mild cognitive impairment Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?Molecular imaging of Alzheimer disease pathology Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study.The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.Utility of oblique coronal images in elderly and cognitively impaired patients Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain Kinetics Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.Validation of 18F-FDG-PET Single-Subject Optimized SPM Procedure with Different PET Scanners.Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.Non-Alzheimer's disease-related memory impairment and dementia.Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease Usefulness of 3-dimensional stereotactic surface projection FDG PET images for the diagnosis of dementia.Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants?Memory performance-related dynamic brain connectivity indicates pathological burden and genetic risk for Alzheimer's disease.Lipidomics of Alzheimer's disease.Advances in imaging-genetic relationships for Alzheimer's disease: clinical implications.FDG-PET Contributions to the Pathophysiology of Memory Impairment.A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.Framingham Risk Score and the Risk of Progression from Mild Cognitive Impairment to Dementia.Non human primate models for Alzheimer's disease-related research and drug discovery.Simultaneous PET-MRI Studies of the Concordance of Atrophy and Hypometabolism in Syndromic Variants of Alzheimer's Disease and Frontotemporal Dementia: An Extended Case Series.Combining SPECT and Quantitative EEG Analysis for the Automated Differential Diagnosis of Disorders with Amnestic Symptoms.The emerging role of PET imaging in dementia.The first genetic biomarker for dementia with Lewy bodies.Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.Regional glucose hypometabolic spread within the primary motor cortex is associated with amyotrophic lateral sclerosis disease progression: A fluoro-deoxyglucose positron emission tomography study.FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.Visual Rating of Posterior Atrophy as a Marker of Progression to Dementia in Mild Cognitive Impairment Patients.

P2860

Q24186399-D7898B14-A02C-41AF-A10D-A9D2E4988D50 Q26825442-8BA8CD68-342F-4407-A507-D00AA17C70F0 Q30366283-2BC2D1DE-5B02-47A4-97F3-E72A12A2C864 Q30844186-D41B15BB-76D2-4E02-90E2-992EBF2F3E82 Q30870223-3A9337F4-BC4B-4D0F-8C07-5A0D9806B725 Q30883711-B080CBAA-CCEF-45EA-BCCC-CA7D5AFA1137 Q30996733-64CFD2E7-8684-4E1D-B62A-F5E8B2B58D94 Q31033080-0496CD4F-F489-48B2-AA1E-E60DBB1B5830 Q33782788-593F1A4C-B911-4742-8F2E-6CBCB485AAE8 Q34426744-E221CE2E-BE16-49B5-9731-D0A02C6FAC16 Q34477727-E15F0AF8-120D-454D-B14F-6A8370164ACF Q34629872-E2275A5B-DA5E-463E-978B-CFFC4895859B Q34651135-AB09A4B1-D2C9-450D-AC62-F01C9C2F9313 Q34988405-C3996EFF-F12C-4CF1-9B26-AB7FAD02EFBD Q34989647-748E46E3-06DE-4887-8BE8-5433D5C9A783 Q35291308-D2F08E87-04AE-4C11-82E0-4D1559293683 Q35529180-89C19B2A-1FC2-47D3-A880-80710016D9AA Q35686223-E09EB6FC-627D-42AE-8EE6-413D92D62736 Q35765058-4FD7923F-8E8C-4053-A5C5-744831E1577A Q36243629-316CD4BD-9523-40D4-A17A-4A7E01475978 Q36929890-20D02FA3-D587-4046-9F62-E6C356B08DD8 Q37503811-68B20BC3-2555-495F-96AA-EE974E1E59B9 Q37559815-339F623B-7A20-4595-882B-1CD03CE7665C Q37606199-8D23D463-D257-44BA-A333-66E653E7E9A5 Q37690944-B7A07E7B-EC12-4B9C-A3BC-C1C975E975A0 Q37731606-F32765F8-8F7A-4586-8652-834A3D4BDB7E Q38191024-6EF08A0E-F602-4415-A81D-188E60046EB1 Q38196862-D0FEF34B-8C58-4908-82E1-A1BE718409B6 Q38576278-C2AA7174-551D-41AD-B30E-D64193582295 Q38697140-519D7D1D-0E3B-4FED-BDB1-80FA9BD1117D Q38742995-1BCCA117-81B8-4934-B648-3D73CF09C5AD Q38783343-BC8AEDAF-69A9-44FA-BDF9-9718AFA337BC Q38960508-DC8FEF6F-8B7F-4C81-9B83-63A45CF94576 Q41299901-5800F904-6472-499E-A98E-7902112DA3A5 Q42701971-DCE1C6D8-5DE3-4E9D-8FBC-7BE1287C7747 Q43528737-FF382838-2390-4EFD-8301-D14BC4868188 Q46133238-FEA1FFB4-B258-4FF2-8A75-0D24564C3964 Q47142121-450A69AD-747B-429B-A095-054B53B7D73F Q47553874-429DDA9C-A53D-405C-B18A-962FEF70935B Q47684888-78484ADE-047F-45E9-8060-F930371D325C

P2860

Imaging markers for Alzheimer disease: which vs how

http://www.wikidata.org/entity/Q27001254

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Imaging markers for Alzheimer disease: which vs how

@ast

Imaging markers for Alzheimer disease: which vs how

@en

Imaging markers for Alzheimer disease: which vs how

@nl

type

label

Imaging markers for Alzheimer disease: which vs how

@ast

Imaging markers for Alzheimer disease: which vs how

@en

Imaging markers for Alzheimer disease: which vs how

@nl

prefLabel

Imaging markers for Alzheimer disease: which vs how

@ast

Imaging markers for Alzheimer disease: which vs how

@en

Imaging markers for Alzheimer disease: which vs how

@nl

P1433

Q27001254-B6AD1A36-13D5-4639-A9BC-92A613E2D2DE

P1476

Q27001254-AEAEF001-CF31-457B-8408-6D0BFC7F5F24

P2093

Q27001254-2BBE7268-4C8C-49A7-85A4-D6ECC3723347

Q27001254-52690E58-FF04-49C7-BDE9-6FD494A40A49

Q27001254-5734021B-6C27-43F9-95D8-C4E93670330D

Q27001254-6A59CB38-2CC3-41A1-AC9F-09AF0C71B8DF

Q27001254-6BF06A6C-1725-4F33-9121-89E57CF7D4DC

Q27001254-7D4DF599-4784-49E4-B709-F94B1246736A

Q27001254-869247D9-1651-41A6-A864-D3D39550B74D

Q27001254-8F5DC8B3-B207-4732-9C89-118052BAA7EA

Q27001254-97BAFAEE-B57A-43F6-B820-5315641C67D0

Q27001254-98958CCB-A006-40B0-8B39-02C055F0C384

P2860

Q27001254-0FFA48D6-0D5E-4712-8FF0-405B7C46478B

Q27001254-19DCD92F-8622-47C2-AF0E-611153DC2ACD

Q27001254-1A1493A9-F0EA-4703-A451-6E40AA783669

Q27001254-1E18EF8D-3DF6-4389-BA8A-890926F2E2AF

Q27001254-2A841C9B-145A-4B20-859E-E3BC20C667D2

Q27001254-31D39737-9E37-412A-91B5-31884F5727AE

Q27001254-32EBB2B0-C6B1-40DC-A893-9BA9CADCCF88

Q27001254-380EFEC3-01DC-4F81-85D4-A4BC0DF7547A

Q27001254-3A443568-87E2-4F36-BA7A-5957E920A8E4

Q27001254-3AAFC9A6-F2E3-4B36-80A4-28E43D550108

P304

Q27001254-DF8DEB74-1C3E-4681-9A48-05AE382FE478

P31

Q27001254-4FCC7856-9790-4180-B401-B85EBB0AFEEC

P356

Q27001254-4524BA66-CB1A-4050-8129-CF7F4571C885

P407

Q27001254-619E4489-A51D-4FB7-B281-FEB23DA6726D

P433

Q27001254-AE03AB89-4A36-41A3-883D-F172368BDF71

P478

Q27001254-6FB4E795-1AC7-4FDE-B8E4-0CB61CC2D15C

P50

Q27001254-31100697-3E9D-49C9-90B0-23D40E31EDF7

Q27001254-3E0D23EC-4CCF-4F93-BE6A-849A172E5B53

Q27001254-3FE9C015-7675-4D1B-B883-E89FFF33AF78

Q27001254-4057F94F-39FA-465D-87A1-18ED5B1B2FDC

Q27001254-4722EA4F-91A9-4317-A302-39300747E34C

Q27001254-7039C15A-7531-4402-9FC6-1BAFFE2B9D2B

Q27001254-89D58A89-3250-42AB-BB16-D0A6961EA91D

Q27001254-9E066EED-4993-42A9-B8A7-30C9C17FE271

Q27001254-A9946213-6E53-4297-B7B2-A3E09A6F593F

Q27001254-C3C49A23-7B3C-4B39-9316-82735CF799B6

P577

Q27001254-C98079FE-A682-48FA-8E8C-9E77102E3031

P698

Q27001254-735E4001-67F8-4CEF-A1F3-8203C218479C

P921

Q27001254-AE875498-274B-491F-A670-13C25602A796

P932

Q27001254-F21325F0-B878-4CEA-B6FA-095969871764

P356

WNL.0B013E31829D86E8

P1433

P1476

Imaging markers for Alzheimer disease: which vs how

@en

P2093

Charles Decarli

http://www.w3.org/2001/XMLSchema#string

Christopher C Rowe

http://www.w3.org/2001/XMLSchema#string

Clifford R Jack

http://www.w3.org/2001/XMLSchema#string

Eric M Reiman

http://www.w3.org/2001/XMLSchema#string

Frederik Barkhof

http://www.w3.org/2001/XMLSchema#string

Gael Chételat

http://www.w3.org/2001/XMLSchema#string

ISTAART's NeuroImaging Professional Interest Area

http://www.w3.org/2001/XMLSchema#string

Karl Herholz

http://www.w3.org/2001/XMLSchema#string

Keith A Johnson

http://www.w3.org/2001/XMLSchema#string

Maria C Carrillo

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic Review of the Diagnostic Accuracy of 99mTc-HMPAO-SPECT in Dementia

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature

Alliance for aging research AD biomarkers work group: structural MRI.

Clinical amyloid imaging in Alzheimer's disease.

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain

Measuring the thickness of the human cerebral cortex from magnetic resonance images

P304

487-500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E31829D86E8

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni B. Frisoni

David J. Brooks

Lars-Olof Wahlund

Patrizio Pasqualetti

Martina Bocchetta

Agneta Nordberg

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23897875

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3776529

http://www.w3.org/2001/XMLSchema#string